Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema

Trial Profile

A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Razuprotafib (Primary) ; Ranibizumab
  • Indications Diabetic macular oedema
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TIME-2
  • Sponsors Aerpio Therapeutics
  • Most Recent Events

    • 02 May 2019 Data from TIME-2 and TIME-2b presented in an Aerpio Pharmaceuticals Media Release.
    • 02 May 2019 According to an Aerpio Pharmaceuticals media release, data from TIME-2 and TIME-2b were presented at The Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting.
    • 28 Feb 2018 Results published in Aerpio Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top